Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.

Cryptococcus neoformans is the most common cause of meningitis amongst adult Africans with HIV/AIDS. The widespread use of fluconazole may lead to the emergence of isolates with reduced susceptibility. We studied C. neoformans isolates from HIV-infected patients with cryptococcal meningitis. Genotyping and antifungal testing were performed to assess the genetic diversity, occurrence of mixed infections and in vitro activity of antifungal agents. Isolates were recovered from cerebrospinal fluid prior to systemic antifungal treatment. Six isolates were studied for each sample (a total of 114 isolates from 19 patients). Serotyping was performed via LAC 1 and CAP 64 gene amplification and genotyping was performed using phage M13 core, (GACA)4 and (GTG)5 primers and restriction polymorphism analysis of the URA5 gene. Susceptibilities for amphotericin B, flucytosine, fluconazole, voriconazole and posaconazole were tested by the Sensititre YeastOne® method. All strains were identified as C. neoformans var. grubii serotype A. We identified nine major genotypes. Up to two genotypes were identified in the same sample. None of the isolates were resistant to the studied drugs. However, 13 of 114 strains exhibited a reduced susceptibility to fluconazole and 13 of 114 strains exhibited a reduced susceptibility to flucytosine. No correlation was found between the genotype and susceptibility. This study confirms the prevalence of C. neoformans serotype A in Cameroon. Two genotypes may be responsible for a single episode of cryptococcosis. The possibility of mixed infection and diminished susceptibility to fluconazole or flucytosine must be considered for the management of cryptococcosis.

[1]  J. Guarro,et al.  Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. , 2012, Medical mycology.

[2]  P. Mathur,et al.  Comparative Analysis of the Vitek 2 Antifungal Susceptibility System and E-test with the CLSI M27-A3 Broth Microdilution Method for Susceptibility Testing of Indian Clinical Isolates of Cryptococcus neoformans , 2012, Mycopathologia.

[3]  T. Boekhout,et al.  In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia. , 2011, Journal of medical microbiology.

[4]  A. Chowdhary,et al.  In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. , 2011, Journal of medical microbiology.

[5]  J. Baddley,et al.  Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya , 2011, Mycoses.

[6]  J. Meis,et al.  Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis , 2010, BMC infectious diseases.

[7]  F. Dromer,et al.  Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen Cryptococcus neoformans , 2010, mBio.

[8]  S. Jaffar,et al.  Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  C. Klaassen.  MLST versus microsatellites for typing Aspergillus fumigatus isolates. , 2009, Medical mycology.

[10]  W. Liao,et al.  Simultaneous identification of molecular and mating types within the Cryptococcus species complex by PCR-RFLP analysis. , 2008, Journal of medical microbiology.

[11]  W. Liao,et al.  Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. , 2008, FEMS yeast research.

[12]  J. Meis,et al.  In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba , 2008, Antimicrobial Agents and Chemotherapy.

[13]  O. Lortholary.  Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  K. Nakamura,et al.  Serotype identification of Cryptococcus neoformans by multiplex PCR , 2007, Mycoses.

[15]  S. Mathoulin-Pélissier,et al.  Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study , 2007, PLoS medicine.

[16]  K. Thong,et al.  Determination of molecular types and genetic heterogeneity of Cryptococcus neoformans and C. gattii in Malaysia. , 2006, Medical mycology.

[17]  Y. Germani,et al.  Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. , 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  W. Meyer,et al.  Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. , 2006, FEMS yeast research.

[19]  F. Dromer,et al.  Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. , 2006, FEMS yeast research.

[20]  J. Ouhon,et al.  Étude biochimique et sérotypique de 40 souches de Cryptococcus neoformans isolées de patients VIH+ à Abidjan (Côte-d'Ivoire) , 2006 .

[21]  F. Ayala,et al.  Clonal population structure and genetic diversity of Candida albicans in AIDS patients from Abidjan (Côte d'Ivoire). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Pfaller,et al.  Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004) , 2005, Journal of Clinical Microbiology.

[23]  M. Pfaller,et al.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. , 2004, Diagnostic microbiology and infectious disease.

[24]  W. Meyer,et al.  Molecular Typing of IberoAmerican Cryptococcus neoformans Isolates , 2003, Emerging infectious diseases.

[25]  B. Lebeau,et al.  Genetic Polymorphism of Aspergillus fumigatus in Clinical Samples from Patients with Invasive Aspergillosis: Investigation Using Multiple Typing Methods , 2001, Journal of Clinical Microbiology.

[26]  W. Hop,et al.  Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. , 2001, Microbiology.

[27]  Ts,et al.  Combination flucytosine and high dose fluconazole is superior to fluconazole monotherapy for cryptococcal meningitis: a randomized trial in Malawi , 2010 .

[28]  Thomas S Harrison,et al.  Cryptococcal meningitis. , 2004, British medical bulletin.

[29]  M. Cogliati,et al.  Genotyping Cryptococcus neoformans var. neoformans with specific primers designed from PCR-fingerprinting bands sequenced using a modified PCR-based strategy. , 2000, Medical mycology.

[30]  T. Sorrell,et al.  Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA — a pilot study to standardize techniques on which to base a detailed epidemiological survey , 1999, Electrophoresis.